<DOC>
	<DOCNO>NCT00000816</DOCNO>
	<brief_summary>To determine whether gradual initiation sulfamethoxazole/trimethoprim ( SMX/TMP ) reduce incidence treatment-limiting adverse reaction compare routine initiation drug Pneumocystis carinii pneumonia ( PCP ) prophylaxis HIV-infected patient . Although number clinical trial demonstrate superiority SMX/TMP PCP prophylaxis , incidence adverse reaction medication high . In pilot study patient initiate SMX/TMP prophylaxis gradually increase dose 2 week , significant adverse reaction occur .</brief_summary>
	<brief_title>Gradual Initiation Sulfamethoxazole/Trimethoprim Primary Pneumocystis Carinii Pneumonia Prophylaxis</brief_title>
	<detailed_description>Although number clinical trial demonstrate superiority SMX/TMP PCP prophylaxis , incidence adverse reaction medication high . In pilot study patient initiate SMX/TMP prophylaxis gradually increase dose 2 week , significant adverse reaction occur . Patients randomize receive either gradually increase dos SMX/TMP suspension routine daily initiation SMX/TMP double strength ( DS ) tablets 2 week . All patient switch receive open-label SMX/TMP DS tablet daily 10 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed clinically indicate : Recombinant erythropoietin ( rEPO ) GCSF . Allowed symptomatic treatment mild study drug toxicity : Antipyretics analgesic ( ibuprofen ) . Antihistamines ( diphenhydramine HCl ) . Terfenadine astemizole ( allow concomitant antifungal macrolide use ) . Systemic steroid . Patients must : HIV infection . CD4 count &lt; = 250 cells/mm3 OR history presence thrush . No history confirm probable pneumocystosis . NOTE : Pregnant woman exclude , safety issue discuss patient prior enrollment . This study appropriate prisoner participation . Coenrollment ongoing ACTG antiretroviral study permit provide new study drug add patient 's drug regimen 4 week initiation SMX/TMP . Prior Medication : Allowed : Prior aerosolized pentamidine dapsone primary PCP prophylaxis . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Known adverse reaction sulfa , trimethoprim , SMX/TMP . Inability comply dose schedule complete dosing record . Concurrent Medication : Excluded : Procysteine . Glutathione . Nacetylcysteine ( NAC ) . Antihistamines ( unless use symptomatic treatment study drug toxicity ) . Systemic corticosteroid ( unless use replacement purpose ) . Leucovorin calcium ( unless use symptomatic treatment study drug toxicity ) . TMP sulfa drug outside study . Prior Medication : Excluded time : Prior SMX/TMP primary PCP prophylaxis . Excluded within 4 week prior study entry : Initiation antiretroviral agent . Initiation antiinfective agent ( include SMX/TMP another indication ) . Excluded within 2 week prior study entry : Antihistamines . Procysteine . Glutathione . Nacetylcysteine ( NAC ) . Systemic corticosteroid ( unless use replacement purpose ) . Leucovorin calcium . TMP sulfa drug separately .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Sulfamethoxazole-Trimethoprim</keyword>
</DOC>